Genmab A/S

18.90
0.21 (1.12%)
At close: Feb 11, 2025, 3:59 PM
18.80
-0.53%
After-hours Feb 11, 2025, 04:16 PM EST
undefined%
Bid 18.5
Market Cap 12.01B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 1
PE Ratio (ttm) 18.9
Forward PE n/a
Analyst Buy
Ask 19.14
Volume 1,135,624
Avg. Volume (20D) 1,361,086
Open 19.05
Previous Close 18.69
Day's Range 18.87 - 19.13
52-Week Range 18.64 - 31.88
Beta undefined

About GMAB

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esoph...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 1, 2009
Employees 2,635
Stock Exchange NASDAQ
Ticker Symbol GMAB

Analyst Forecast

According to 7 analyst ratings, the average rating for GMAB stock is "Buy." The 12-month stock price forecast is $49, which is an increase of 159.26% from the latest price.

Buy 71.43%
Hold 28.57%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Genmab A/S is scheduled to release its earnings on Feb 12, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
-3.81%
Genmab shares are trading lower. The company repor... Unlock content with Pro Subscription
5 months ago
-2.02%
Genmab shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral.